WallStreetZenWallStreetZen

NASDAQ: FOLD
Amicus Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FOLD past revenue growth

How has FOLD's revenue growth performed historically?
Company
21.3%
Industry
144.63%
Market
17.55%
FOLD's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FOLD's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FOLD's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FOLD earnings and revenue history

Current Revenue
$399.4M
Current Earnings
-$151.6M
Current Profit Margin
-38%

FOLD Return on Equity

Current Company
-119.5%
Current Industry
-63.5%
Current Market
188%
FOLD's Return on Equity (-119.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when FOLD announces earnings.

FOLD Return on Assets

Current Company
-20.4%
Current Industry
2.9%
FOLD is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FOLD Return on Capital Employed

Current Company
-16.38%
Current Industry
19.5%
FOLD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FOLD vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FOLD$399.36M-$92.08M-$151.58M+34.35%N/A
XENE$0.00-$179.14M-$182.39M-100.00%N/A
IDYA$23.39M-$108.95M-$112.96M+58.18%N/A
CRNX$4.01M-$212.22M-$214.53M+10.57%N/A
IMCR$249.43M-$50.00M-$55.29M+53.19%N/A
View Top Biotech Stocks

FOLD earnings dates

Next earnings date
Jun 6, 2024

Amicus Therapeutics Earnings & Revenue FAQ

What were FOLD's earnings last quarter?

On Invalid Date, Amicus Therapeutics (NASDAQ: FOLD) reported Q4 2023 earnings per share (EPS) of -$0.11, up 42.11% year over year. Total Amicus Therapeutics earnings for the quarter were -$33.84 million. In the same quarter last year, Amicus Therapeutics's earnings per share (EPS) was -$0.19.

If you're new to stock investing, here's how to buy Amicus Therapeutics stock.

What was FOLD's earnings growth in the past year?

As of Q2 2024, Amicus Therapeutics's earnings has grown year over year. Amicus Therapeutics's earnings in the past year totalled -$151.58 million.

What is FOLD's earnings date?

Amicus Therapeutics's earnings date is Invalid Date. Add FOLD to your watchlist to be reminded of FOLD's next earnings announcement.

What was FOLD's revenue last quarter?

On Invalid Date, Amicus Therapeutics (NASDAQ: FOLD) reported Q4 2023 revenue of $115.08 million up 30.63% year over year. In the same quarter last year, Amicus Therapeutics's revenue was $88.10 million.

What was FOLD's revenue growth in the past year?

As of Q2 2024, Amicus Therapeutics's revenue has grown 21.3% year over year. This is 123.33 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Amicus Therapeutics's revenue in the past year totalled $399.36 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.